Royalty Pharma Plc (RPRX)
61.33
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
61.32
-0.01
(-0.02%)
Pre-Market: 20:00
Royalty Pharma Enterprise Value : 38.42B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 38.42B |
| August 21, 2026 | 38.41B |
| August 20, 2026 | 38.08B |
| August 19, 2026 | 38.59B |
| August 18, 2026 | 37.68B |
| August 17, 2026 | 37.58B |
| August 14, 2026 | 37.20B |
| August 13, 2026 | 37.18B |
| August 12, 2026 | 37.47B |
| August 11, 2026 | 36.84B |
| August 10, 2026 | 36.92B |
| August 07, 2026 | 36.38B |
| August 06, 2026 | 36.60B |
| August 05, 2026 | 36.82B |
| August 04, 2026 | 36.70B |
| August 03, 2026 | 36.56B |
| July 31, 2026 | 37.12B |
| July 30, 2026 | 37.39B |
| July 29, 2026 | 37.46B |
| July 28, 2026 | 37.81B |
| July 27, 2026 | 37.26B |
| July 24, 2026 | 37.30B |
| July 23, 2026 | 37.39B |
| July 22, 2026 | 37.25B |
| July 21, 2026 | 37.12B |
| Date | Value |
|---|---|
| July 20, 2026 | 36.62B |
| July 17, 2026 | 37.01B |
| July 16, 2026 | 37.17B |
| July 15, 2026 | 36.18B |
| July 14, 2026 | 35.89B |
| July 13, 2026 | 36.24B |
| July 10, 2026 | 36.23B |
| July 09, 2026 | 36.91B |
| July 08, 2026 | 37.10B |
| July 07, 2026 | 36.84B |
| July 06, 2026 | 36.45B |
| July 02, 2026 | 36.83B |
| July 01, 2026 | 35.94B |
| June 30, 2026 | 36.07B |
| June 29, 2026 | 36.72B |
| June 26, 2026 | 36.34B |
| June 25, 2026 | 35.66B |
| June 24, 2026 | 35.48B |
| June 23, 2026 | 35.95B |
| June 22, 2026 | 35.16B |
| June 18, 2026 | 34.89B |
| June 17, 2026 | 35.22B |
| June 16, 2026 | 35.45B |
| June 15, 2026 | 35.47B |
| June 12, 2026 | 35.74B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 543.37B |
| Johnson & Johnson | 685.82B |
| Viatris, Inc. | 31.32B |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 81.49M |
| Revenue (Quarterly) | 674.14M |
| Total Expenses (Quarterly) | 656.26M |
| EPS Diluted (Quarterly) | 0.04 |
| Gross Profit Margin (Quarterly) | 99.81% |
| Profit Margin (Quarterly) | 12.09% |
| Earnings Yield | 3.06% |
| Operating Earnings Yield | 4.90% |
| Normalized Earnings Yield | 2.880 |